frustration ++, page-5

This company will re-rate when there is tangible money coming in the door, not before. When funding is tight, people look for more immediate returns. A big quarter with diclo revenues and Elixia and ENA sales, solid proof points for TPM being an earner, and it will be off to the races.

As to oxy shareprice bumps, biotechs in development are behaving very strangely these days and not getting significant re-rates on anything, including FDA Phase completions. The news has to be stunning to shift things without a deal or money in.

Everyone is waiting for the returns.